Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Change in Accured Expenses: 2009-2024

Historic Change in Accured Expenses for Iovance Biotherapeutics (IOVA) over the last 15 years, with Dec 2024 value amounting to $8.6 million.

  • Iovance Biotherapeutics' Change in Accured Expenses fell 56.70% to $5.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.6 million, marking a year-over-year decrease of 16.89%. This contributed to the annual value of $8.6 million for FY2024, which is 56.62% down from last year.
  • Iovance Biotherapeutics' Change in Accured Expenses amounted to $8.6 million in FY2024, which was down 56.62% from $19.8 million recorded in FY2023.
  • In the past 5 years, Iovance Biotherapeutics' Change in Accured Expenses ranged from a high of $24.1 million in FY2020 and a low of -$4.7 million during FY2022.
  • Its 3-year average for Change in Accured Expenses is $7.9 million, with a median of $8.6 million in 2024.
  • Per our database at Business Quant, Iovance Biotherapeutics' Change in Accured Expenses slumped by 122.74% in 2022 and then skyrocketed by 520.46% in 2023.
  • Iovance Biotherapeutics' Change in Accured Expenses (Yearly) stood at $24.1 million in 2020, then fell by 14.21% to $20.7 million in 2021, then tumbled by 122.74% to -$4.7 million in 2022, then spiked by 520.46% to $19.8 million in 2023, then plummeted by 56.62% to $8.6 million in 2024.